17th FDA Approval At Butchertown Clinical Trials

Logo EIN Presswire
EIN Presswire

Butchertown Clinical Trials facility in Louisville, Kentucky

Butchertown Clinical Trials and The Eye Care Institute Announce Our 17th FDA Approval or Clearance

Our clinical trials site delivers excellent data with high enrollment rates. Our 17th FDA approval or clearance is further evidence of our staff's commitment to clinical trials excellence.”
— Mark Prussian
LOUISVILLE, KENTUCKY, UNITED STATES, January 24, 2023 /EINPresswire.com/ -- Visant Medical, a Menlo Park, CA company, announced FDA Clearance for its patented canalicular occlusive device. The device blocks tear drainage through the canalicular system in patients experiencing both signs and symptoms of dry eye disease for up to six months.

John C. Meyer, MD, of The Eye Care Institute and Butchertown Clinical Trials, was the principal investigator for the proof of concept research leading to the clinical trials being submitted to the FDA for clearance of this novel approach to treating signs and symptoms of dry eye disease. Designers brought several prototypes of the device to our facility. I was able to implant several versions of the prototype to determine which was most effective in meeting the scientific goals. Even in the early stages of development, it was clear this device was headed for success, Meyer said.

We are pleased to have received FDA clearance for our innovative dry eye product, which is based on a proprietary formulation of cross-linked hyaluronic acid, said Vartan Ghazarossian, Ph.D., Co-founder, President, and CEO of Visant Medical. Upon commercialization, the product will be offered as a kit that includes the device in a sterile syringe, along with compatible cannulas for delivery of the device.

Mark Prussian, CEO of Butchertown Clinical Trials and The Eye Care Institute, said, I recall that when Dr. Ghazarossian came to my office, he was laser-focused on engineering and design of this device. Together, we compared retail hyaluronic acid, which my wife, Betsy Prussian, purchased at a local Trader Joes, with the large quantities his firm was buying for research and development.

This is the 17th FDA approved or cleared drug or device for Louisville, KY based Butchertown Clinical Trials. Three additional drugs or devices researched at Butchertown Clinical Trials are currently before the FDA awaiting approval.
# # #

For More Information, Contact Mark Prussian at Butchertown Clinical Trials

Mark Prussian
Butchertown Clinical Trials
+1 502-589-1500
email us here
Visit us on social media:
Facebook
LinkedIn

Continue read on einpresswire.com

Logo PR Newswire
HealthPress Release2023-01-24 13:00:00
FDA's Decision Forthcoming for Innovative Test with Agency's Breakthrough Device Designation ST. LOUIS, Jan. 24, 2023 /PRNewswire/ -- Geneoscopy Inc., a life...

Logo Benzinga
Business / FinanceBy Globe Newswire2023-01-23 23:55:27
Receives greenlight from the FDA for Phase 1/2a clinical trial of CNA3103 On track to commence patient enrollment during the first half 2023 ADELAIDE,...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-24 12:36:00
Treatment IDE Will Provide Opportunity to Treat Additional Patients in the US SAN RAMON, Calif., Jan. 24, 2023 /PRNewswire/ -- BioVentrix, Inc., a privately...

Logo PR Newswire
HealthPress Release2023-01-24 12:36:00
Treatment IDE Will Provide Opportunity to Treat Additional Patients in the US SAN RAMON, Calif., Jan. 24, 2023 /PRNewswire/ -- BioVentrix ®, Inc., a...

Logo PR Newswire
HealthPress Release2023-01-24 17:40:00
SILVER SPRING, Md., Jan. 24, 2023 /PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the...

Logo GlobeNewswire
SciencePress Release2023-01-24 13:00:00
CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted...

Logo GlobeNewswire
SciencePress Release2023-01-24 12:30:00
SAN DIEGO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the...

Logo GlobeNewswire
SciencePress Release2023-01-23 23:55:00
Receives greenlight from the FDA for Phase 1/2a clinical trial of CNA3103 On track to commence patient enrollment during the first half 2023 ADELAIDE,...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-24 18:15:00
Recently published University of Arkansas study examined the patient-specific risk factors and clinical outcomes associated with contaminated blood cultures...

Logo GlobeNewswire
SciencePress Release2023-01-24 17:12:00
Figure 1 PET scans showing mouse brain before (left) and after (right) MS induction (brain encircled in a dashed white line). The enzyme dCK becomes...

Logo PR Newswire
TechnologyPress Release2023-01-24 14:00:00
Aetion and FDA will use the Aetion Evidence Platform ® to study crucial oncology research questions to advance the mission of the Oncology Center of...

Logo GlobeNewswire
SciencePress Release2023-01-24 09:00:00
AVT02 as Simlandi is the first biosimilar approved under the strategic partnership between Alvotech and Bioventure REYKJAVIK, Iceland and DUBAI, United Arab...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-24 12:45:00
Phase 1/2 clinical trial expected to launch in early 2023 and will evaluate safety and preliminary impact on disease activity of IMPT-314 WEST HILLS, Calif.,...

Logo EIN Presswire
HealthPress Release2023-01-24 15:18:24
Emergen Research Logo Technological advent of robotic surgery aids, 3D Printing technology for craniomaxillofacial surgery, would lead to the growth...

Logo PR Newswire
HealthPress Release2023-01-24 18:30:00
NEW YORK, Jan. 24, 2023 /PRNewswire/ -- The ophthalmology therapeutics market by product, type, and geography - forecast and analysis 2023-2027 report has...

Logo PR Newswire
HealthPress Release2023-01-24 12:00:00
REHOVOT, Israel, Jan. 24, 2023 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies...

Logo PR Newswire
HealthPress Release2023-01-24 14:30:00
Designed using the Company's proprietary platform, initial test design remains effective detection tool even after three years of variants and more than 33...

Logo GlobeNewswire
SciencePress Release2023-01-24 13:00:00
SOMERVILLE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (the Company, Finch, or Finch Therapeutics) (Nasdaq: FNCH) today...

Logo GlobeNewswire
SciencePress Release2023-01-24 12:00:00
Regulatory Pathway for a Potential NDA Submission Clarified Following Recent Interactions with the FDA FDA Acknowledged that SHIELD I Pre-specified Subgroup...

Logo PR Newswire
HealthPress Release2023-01-24 17:18:00
Susan G. Komen Commends Bill Introductions; Urges Quick Passage SAINT PAUL, Minn., Jan. 24, 2023 /PRNewswire/ -- Susan G. Komen ®, the world's leading breast...